Please assess the completion status of the following clinical trial:

Trial Title: Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologic diagnosis of nasopharyngeal carcinoma~* Distance metastasis at least 6 months after radical treatment~* Not suitable for local treatment, e.g. surgery, TACE~* At least one measurable lesion~* Estimate survival \>3months~* Range from 18～70 years old~* PS 0\~1~* WBC count ≥ 4×109/L，Hemoglobin ≥ 100g/L， platelet count ≥ 100×109/L~* ALT or AST \< 2.5×ULN、bilirubin \< 1.5×ULN~* 0Serum creatinine \< 1.5×ULN~Exclusion Criteria:~* Central nervous system metastases~* Suitable for local treatment~* Second malignancy within 5 years~* Precious therapy with an investigational agent~* Uncontrolled seizure disorder or other serious neurologic disease~* ≥ Grade Ш allergic reaction to any drug including in this study~* Clinically significant cardiac or respiratory disease~* Creatinine clearance \< 30ml/min~* Drug or alcohol addition~* Do not have full capacity for civil acts~* Severe complication, active infection~* Concurrent immunotherapy or hormone therapy for other diseases~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- PF+ Nimotuzumab (Type: EXPERIMENTAL): Patients treated with cisplatin and 5-Fu combined with nimotuzumab

Based on this trial design, predict the completion outcome and termination type (if applicable).